- Funds will support Phase 3 Trials for Crohn's Disease, Pouchitis and
Other Pipeline Products -
SAN DIEGO, Feb. 20 /PRNewswire/ -- Ocera Therapeutics, a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases, has announced the completion of a $35.5 million Series C financing from a syndicate of highly-regarded investors.
New investor Montagu Newhall Associates is leading the round and is joined by InterWest Partners; AgeChem Venture Fund; Cross Creek Capital, an affiliate of Wasatch Advisors; FinTech and CDIB BioScience. Previous investors, Domain Associates, Sofinnova Ventures, and Thomas, McNerney & Partners, also participated in the round. To date, Ocera has raised a total of $62 million. In conjunction with the financing, Linda Grais of InterWest Partners will take a seat on the Ocera Board of Directors representing Montagu Newhall Associates and the Series C investors.
"I am extremely pleased with the investor confidence we've seen from this oversubscribed financing round," commented Laurent Fischer, M.D., co-founder, president and CEO of Ocera Therapeutics. "We are privileged to have attracted a syndicate of renowned investors with specific expertise in the gastrointestinal market as well as international and crossover investors and we welcome Linda Grais' guidance as she joins our board of directors."
Linda Grais M.D., J.D., is a partner with InterWest Partners and brings
a wide array of experience to the team. Prior to InterWest, Dr. Grais
served as founder and executive vice president of SGX Pharmaceuticals and
was an attorney at Wilson Sonsini Goodrich & Rosati. Before practicing law,
Dr. Grais worked as an assistant clinical professor of Internal Medicine
and Critical Care at the University of California, San Francisco. She also
served as a consultant to the Institute of Medicin
|SOURCE Ocera Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved